Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility ofHuman Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors

ABSTRACT The clinical use of the human immunodeficiency virus (HIV) fusion inhibitor enfuvirtide (ENF) can select for drug-resistant HIV-1 strains bearing mutations in the HR1 region of the viral envelope (Env) protein. We analyzed the properties of multiple Env proteins isolated from five patients who experienced an initial decline in viral load after ENF therapy followed by subsequent rebound due to emergence of ENF-resistant HIV-1. Prior to ENF therapy, each patient harbored genetically and phenotypically diverse Env proteins that used CCR5 and/or CXCR4 to elicit membrane fusion. Coreceptor usage patterns of the Envs isolated from two patients underwent homogenization following ENF therapy, whereas in the other three patients, recombination appeared to allow the introduction of a single HR1 sequence with ENF resistance mutations into phenotypically distinct Env proteins. Analysis of individual Env clones also revealed that prior to ENF therapy, there was sometimes marked heterogeneity in the susceptibility of individual Env proteins to coreceptor inhibitors. After virologic failure, all Envs acquired resistance to ENF but exhibited no consistent change in their sensitivity to the fusion inhibitor T-1249 or to coreceptor inhibitors. In summary, using patient-derived Env proteins, we found that ENF failure was associated with emergence of high-level resistance to ENF due largely to mutations in HR1 but that susceptibility to other entry inhibitors was unaffected, that in these late-stage patients there was greater clonal variability to coreceptor than to fusion inhibitors, and that recombination events in vivo could sometimes restore Env genotypic and phenotypic heterogeneity by introducing drug-resistant gp41 sequences into heterologous gp120 backgrounds.

[1]  R. Samudrala,et al.  Heptad-Repeat-2 Mutations Enhance the Stability of the Enfuvirtide-Resistant HIV-1 gp41 Hairpin Structure , 2005, Antiviral therapy.

[2]  J. Felsenstein An alternating least squares approach to inferring phylogenies from pairwise distances. , 1997, Systematic biology.

[3]  Michael Greenberg,et al.  Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.

[4]  A. Siccardi,et al.  CXCR4 is a functional coreceptor for infection of human macrophages by CXCR4-dependent primary HIV-1 isolates. , 1998, Journal of immunology.

[5]  R. Doms,et al.  Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian–Human Immunodeficiency Virus Infection , 2003, The Journal of experimental medicine.

[6]  R. Doms,et al.  Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Christine Katlama,et al.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.

[8]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[9]  Robert Blumenthal,et al.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  O. Tenaillon,et al.  Extensive Recombination among Human Immunodeficiency Virus Type 1 Quasispecies Makes an Important Contribution to Viral Diversity in Individual Patients , 2006, Journal of Virology.

[11]  Rebecca Hoh,et al.  Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis , 2006, Journal of acquired immune deficiency syndromes.

[12]  G. Melikyan,et al.  Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion , 2000, The Journal of cell biology.

[13]  Marc Parmentier,et al.  Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.

[14]  E. Poveda,et al.  HIV entry inhibitors: mechanisms of action and resistance pathways. , 2006, The Journal of antimicrobial chemotherapy.

[15]  Roderic D. M. Page,et al.  TreeView: an application to display phylogenetic trees on personal computers , 1996, Comput. Appl. Biosci..

[16]  J. Kappes,et al.  Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120 , 2000, Journal of Virology.

[17]  R. Collman,et al.  CXCR-4 Is Expressed by Primary Macrophages and Supports CCR5-Independent Infection by Dual-Tropic but Not T-Tropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[18]  R. Swanstrom,et al.  Effect of a Protease Inhibitor-Induced Genetic Bottleneck on Human Immunodeficiency Virus Type 1 env Gene Populations , 2005, Journal of Virology.

[19]  A. Trkola,et al.  Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors , 2005, Journal of Virology.

[20]  D. Pillay,et al.  Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41 , 2005, Antimicrobial Agents and Chemotherapy.

[21]  David W. Williamson,et al.  Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. , 2006, The Journal of infectious diseases.

[22]  R. Doms,et al.  Cell-cell fusion assay to study role of chemokine receptors in human immunodeficiency virus type 1 entry. , 1997, Methods in enzymology.

[23]  P. Ravindran,et al.  Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[24]  E. Clercq,et al.  Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.

[25]  T. Matthews,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.

[26]  B. Berkhout,et al.  Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor , 2004, Journal of Virology.

[27]  Douglas D. Richman,et al.  HIV chemotherapy , 2001, Nature.

[28]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[29]  E. De Clercq,et al.  CXCR4 as a Functional Coreceptor for Human Immunodeficiency Virus Type 1 Infection of Primary Macrophages , 1998, Journal of Virology.

[30]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[31]  Cassandra B. Jabara,et al.  Enfuvirtide Resistance Mutations: Impact on Human Immunodeficiency Virus Envelope Function, Entry Inhibitor Sensitivity, and Virus Neutralization , 2005, Journal of Virology.

[32]  S. A. Gallo,et al.  HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. , 2001, Biochemistry.

[33]  S. Shafikhani Factors affecting PCR-mediated recombination. , 2002, Environmental Microbiology.

[34]  D. Bolognesi,et al.  A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion , 1995, Journal of virology.

[35]  C. Wilson,et al.  Stimulation and suppression of PCR-mediated recombination. , 1998, Nucleic acids research.

[36]  M. Markowitz,et al.  Rapid, Transient Changes at theenv Locus of Plasma Human Immunodeficiency Virus Type 1 Populations during the Emergence of Protease Inhibitor Resistance , 1998, Journal of Virology.

[37]  R. Doms,et al.  The entry of entry inhibitors: A fusion of science and medicine , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  L. Pérez-Alvárez,et al.  Long‐term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV‐1 , 2006, Journal of medical virology.

[39]  Michael Greenberg,et al.  Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20) , 2004, Journal of Virology.

[40]  G. D. Miralles,et al.  T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. , 2005, The Journal of infectious diseases.

[41]  B. Cullen,et al.  HIV‐1‐induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR‐5 co‐receptor , 1997, The EMBO journal.

[42]  R. Doms,et al.  HIV-1 coreceptors and their inhibitors. , 2006, Current topics in microbiology and immunology.

[43]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[44]  M. Hirsch,et al.  Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1 , 2005, Antimicrobial Agents and Chemotherapy.

[45]  B. Moss,et al.  Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor , 1992, Journal of virology.

[46]  Lei Jin,et al.  Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates , 2004, AIDS.

[47]  S. Deeks,et al.  A Randomized Pilot Study Comparing Combination Therapy plus Enfuvirtide versus a Treatment Interruption followed by Combination Therapy plus Enfuvirtide , 2005, Antiviral therapy.

[48]  M. Greenberg,et al.  Resistance to enfuvirtide, the first HIV fusion inhibitor. , 2004, The Journal of antimicrobial chemotherapy.

[49]  Nga Nguyen,et al.  Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites , 2003, Journal of Virology.

[50]  H. Guy,et al.  Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.

[51]  B. Kawakami,et al.  Characterization of DNA polymerase from Pyrococcus sp. strain KOD1 and its application to PCR , 1997, Applied and environmental microbiology.

[52]  G. Shaw,et al.  Determinants of Human Immunodeficiency Virus Type 1 Baseline Susceptibility to the Fusion Inhibitors Enfuvirtide and T-649 Reside outside the Peptide Interaction Site , 2004, Journal of Virology.

[53]  Ronald G. Collman,et al.  Preferential Use of CXCR4 by R5X4 Human Immunodeficiency Virus Type 1 Isolates for Infection of Primary Lymphocytes , 2005, Journal of Virology.

[54]  Robyn L Stanfield,et al.  Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor , 2004, Journal of Virology.

[55]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[56]  E. De Clercq,et al.  env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.

[57]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[58]  F. Mammano,et al.  Role of the Envelope Genetic Context in the Development of Enfuvirtide Resistance in Human Immunodeficiency Virus Type 1-Infected Patients , 2006, Journal of Virology.

[59]  V. Trouplin,et al.  Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors , 2003, Journal of Virology.

[60]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.